Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: Implication for models of tardive dyskinesia

1980 ◽  
Vol 69 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Robert B. Glassman ◽  
Harriet N. Glassman
1979 ◽  
Vol 45 (2) ◽  
pp. 415-419 ◽  
Author(s):  
Daniel J. Lonowski ◽  
F. E. Sterling ◽  
Hugh A. King

An ABAB reversal design with matched placebo was employed to assess the acetylcholine precursor, deanol, in the treatment of tardive dyskinesia. Oral dyskinesia was monitored by electromyography in four patients with tardive dyskinesia. A battery of psychological rating scales was also utilized to determine effects of deanol on psychological functioning. Improvement ranged from 35 to 70% dyskinetic symptom reduction in three patients given deanol. The decrease in symptomatology, however, did not reach the level of oral EMG activity observed in a normal control subject. Psychological functioning was generally unaffected, but slight improvement was seen in two subjects.


1992 ◽  
Author(s):  
R. Yassa ◽  
C. Natase ◽  
D. Dupont ◽  
M. Thibeau

2018 ◽  
Vol 11 (4) ◽  
pp. 214-220 ◽  
Author(s):  
Michael A. Cummings ◽  
George J. Proctor ◽  
Stephen M. Stahl
Keyword(s):  

1996 ◽  
Vol 8 (1) ◽  
pp. 27-29 ◽  
Author(s):  
Sunil Rangwani ◽  
Sanjay Gupta ◽  
William Burke ◽  
Jane Potter
Keyword(s):  

1995 ◽  
Vol 52 (19) ◽  
pp. 2137-2138
Author(s):  
Doug T. Russo ◽  
Cheryl L. Bunch
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document